Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism
Pharmacology Research & Perspectives · 2023
DOI: 10.1002/prp2.1052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Sandra Witta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Vinblastine, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Vinblastine (VBL) is a vinca alkaloid‐class cytotoxic chemotherapeutic that causes microtubule disruption and is typically used to treat hematologic malignancies. VBL is characterized by a narrow therapeutic index, with key dose‐limiting toxicities being myelosuppression and neurotoxicity. Pharmacokinetics (PK) of VBL is primarily driven by ABCB1‐mediated efflux and CYP3A4 metabolism, creating potential for drug–drug interaction. To characterize sources of variability in VBL PK, we developed a physiologically based pharmacokinetic (PBPK) model in Mdr1a/b(−/−) knockout and wild‐type mice by incorporating key drivers of PK, including ABCB1 efflux, CYP3A4 metabolism, and tissue‐specific tubulin binding, and scaled this model to accurately simulate VBL PK in humans and pet dogs. To investigate the capability of the model to capture interindividual variability in clinical data, virtual populations of humans and pet dogs were generated through Monte Carlo simulation of physiologic and biochemical parameters and compared to the clinical PK data. This model provides a foundation for predictive modeling of VBL PK. The base PBPK model can be further improved with supplemental experimental data identifying drug–drug interactions, ABCB1 polymorphisms and expression, and other sources of physiologic or metabolic variability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
- School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, USA.
- Department of Surgical and Radiological Sciences, University of California, Davis, California, USA.
- University of California, Davis Comprehensive Cancer Center, Sacramento, California, USA.
- Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, Colorado, USA.
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA.
ORCID-Profile: Daniel L Gustafson
Förderung
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Witta, S., Collins, K. P., Ramirez, D. A., Mannheimer, J. D., Wittenburg, L. A., & Gustafson, D. L. (2023). Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1052
Vancouver
Witta S, Collins KP, Ramirez DA, Mannheimer JD, Wittenburg LA, Gustafson DL. Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1052
BibTeX
@article{Witta2023,
author = {Witta, Sandra and Collins, Keagan P and Ramirez, Dominique A and Mannheimer, Joshua D and Wittenburg, Luke A and Gustafson, Daniel L},
title = {Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism},
journal = {Pharmacology Research & Perspectives},
year = {2023},
doi = {10.1002/prp2.1052}
}
EUVIMED